Nektar Therapeutics (NASDAQ:NKTR) Insider Sells $13,140.00 in Stock

Nektar Therapeutics (NASDAQ:NKTR) insider Jonathan Zalevsky sold 180 shares of the stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $73.00, for a total value of $13,140.00. Following the transaction, the insider directly owned 21,174 shares in the company, valued at approximately $1,545,702. This represents a 0.84% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Jonathan Zalevsky also recently made the following trade(s):

• On Tuesday, January 20th, Jonathan Zalevsky sold 3,867 shares of Nektar Therapeutics stock. The shares were sold at an average price of $35.67, for a total value of $137,935.89.
• On Tuesday, November 25th, Jonathan Zalevsky sold 1,157 shares of Nektar Therapeutics stock. The shares were sold at an average price of $54.28, for a total value of $62,801.96.

Nektar Therapeutics Trading Down 0.2%

NASDAQ NKTR opened at $73.73 on Monday. The business’s 50-day moving average price is $45.81 and its 200 day moving average price is $48.72. Nektar Therapeutics has a twelve month low of $6.45 and a twelve month high of $74.89. The company has a market capitalization of $1.50 billion, a PE ratio of -9.25 and a beta of 1.34.

More Nektar Therapeutics News

Here are the key news stories impacting Nektar Therapeutics this week:

• Positive Sentiment: Zacks Research raised multiple multi‑quarter and full‑year EPS projections (FY2026 and FY2027 were revised to smaller losses), indicating improved analyst expectations for Nektar’s future results — a generally constructive signal for the stock. MarketBeat NKTR
• Positive Sentiment: Nektar announced research collaboration with UCSF to test a TNFR2‑agonist/antibody approach in multiple sclerosis — a meaningful pipeline development that could add long‑term value if clinical data are positive. MSNewsToday: UCSF, Nektar team BioWorld: TNFR2 agonism in MS
• Neutral Sentiment: An AAII piece compared Nektar to another biotech (Harmony Biosciences) as an investment choice — useful context for longer‑term investors but unlikely to move the stock materially on its own. AAII comparison article
• Negative Sentiment: Zacks cut near‑term quarter estimates for Q2 2026 (and separately trimmed Q2 2027), signaling some expected near‑term pressure to results that can weigh on sentiment. MarketBeat NKTR

Institutional Trading of Nektar Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the business. AQR Capital Management LLC raised its position in Nektar Therapeutics by 336.9% in the first quarter. AQR Capital Management LLC now owns 3,640,851 shares of the biopharmaceutical company’s stock valued at $2,463,000 after purchasing an additional 2,807,595 shares during the period. Integrated Wealth Concepts LLC acquired a new stake in shares of Nektar Therapeutics in the first quarter valued at about $68,000. Rhumbline Advisers grew its stake in shares of Nektar Therapeutics by 23.3% in the first quarter. Rhumbline Advisers now owns 221,761 shares of the biopharmaceutical company’s stock valued at $151,000 after buying an additional 41,948 shares in the last quarter. FNY Investment Advisers LLC acquired a new position in Nektar Therapeutics during the 2nd quarter worth approximately $39,000. Finally, Moody Aldrich Partners LLC purchased a new position in Nektar Therapeutics in the 2nd quarter worth approximately $1,173,000. 75.88% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. BTIG Research upped their price target on shares of Nektar Therapeutics from $118.00 to $151.00 and gave the stock a “buy” rating in a research report on Tuesday, February 10th. Wall Street Zen downgraded Nektar Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, November 16th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Nektar Therapeutics in a research report on Monday, December 29th. William Blair upgraded Nektar Therapeutics from a “market perform” rating to an “outperform” rating in a report on Tuesday, February 10th. Finally, Piper Sandler reissued an “overweight” rating and set a $105.00 price target on shares of Nektar Therapeutics in a research report on Monday, January 26th. Eight analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Nektar Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $119.86.

Nektar Therapeutics Company Profile

Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body’s immune system to treat cancer and other serious diseases.

Nektar’s product portfolio and pipeline include a range of clinical-stage and partnered programs.